This peer review is not listed anywhere in the disclosures
STATEMENT OF INDEPENDENCE
As a CME provider accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy to ensure that the content of this educational activity is high-quality, balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Annual Meeting Steering Committee.
DISCLOSURE POLICY
The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined as remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that enables them to make their own judgments about whether these financial relationships may have influenced the educational activity’s exposition or conclusions. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The Endocrine Society has reviewed these relationships to determine which are relevant to this activity's content and has resolved any identified conflicts of interest for these individuals.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Richard J. Auchus, MD, PhD Adrenas (Contracted Research), Aspect Biosystems (Consultant), Crinetics (Consultant and Contracted Research), Lundbeck (Consultant), Lundbeck (Contracted Research), Merck (Consultant), Neurocrine (Consultant and Contracted Research), OMass (Consultant), Vertex (Consultant).
Rodica Busui, MD, PhD Novo Nordisk (Clinical Trial Investigator and Consultant), Averitas Pharma (Consultant), Bayer Inc. (Clinical Trial Investigator and Consultant), Lexicon (Clinical Trial Investigator and Consultant), Roche Diagnostics (Consultant), and Vertex (Consultant).
Maria E. Cabanillas, MD Bayer Inc. (Consultant), EISAI (Research funding), Exelixis (Consultant and Research Funding), Genentech (Research Funding), Lilly (Consultant), Merck (Research Funding), and Novartis (Consultant).
W. Timothy Garvey, MD Novo Nordisk (Advisory Board and Clinical Trial Investigator), AbbVie (Advisory Board), Boehringer-Ingelheim (Advisory Board), Corcept Therapeutics (Advisory Board), Eli Lilly & Company (Advisory Board and Clinical Trial Investigator), Fractyl Health (Advisory Board), Gan & Lee (Advisory Board), Graviton Biosciences (Advisory Board), i2o Therapeutics (Advisory Board), Kaleira (Clinical Trial Investigator), Keros Therapeutics (Advisory Board), Madrigal (Advisory Board), Neurocrine Biosciences (Advisory Board), Pfizer (Advisory Board), Regeneron, (Advisory Board), Roche Pharmaceuticals (Advisory Board and Clinical Trial Investigator), TERNS Pharmaceuticals (Advisory Board and Clinical Trial Investigator), Viking Therapeutics (Clinical Trial Investigator), and Zealand (Advisory Board and Clinical Trial Investigator).
Christian Girgis, MBBS, PhD Theramex (Advisory Board).
Jerry R. Greenfield, MBBS, PhD Novo Nordisk (Recipient of drug and placebo for a study of semaglutide in type 1 diabetes).
Thorvardur R. Halfdanarson, MD Biomea Fusion (Advisory Board), Boehringer Ingelheim (Advisory Board), Camurus (Clinical Trial Investigator), Crinetics (Clinical Trial Investigator), Curium (Advisory Board), Exelixis (Advisory Board and Clinical Trial Investigator), ITM (Clinical Trial Investigator), Novartis (Clinical Trial Investigator), Perspective Therapeutics (Clinical Trial Investigator), RayzeBio (Clinical Trial Investigator), Rezolute (Clinical Trial Investigator), Sanofi (Advisory Board), and Thermo Fisher (Clinical Trial Investigator).
Aliya A. Khan, MD Ascendis Pharma (Grant Recipient).
Sun Y. Lee, MD, MSc Alcimed (Consultant), American Association of Clinical Endocrinology (Honorarium Recipient), Florida Endocrinology Association (Honorarium Recipient), and Gudiepoint (Consultant).
Jennifer L. Miller, MD, MS Rhythm Therapeutics (Clinical Trial Investigator) and Soleno Therapeutics (Clinical Trial Investigator).
Oscar L. Morey-Vargas, MD Asofarma (Teaching and Speaking).
Lisa Nachtigall, MD Camurus (Advisory Board), Chiesi (Advisory Board, Consultant, and Contracted Research), Crinetics (Advisory Board and Consultant), and Recordati Rare Disease (Advisory Board and Grant Recipient).
John Newell-Price, MD, PhD Crinetics (Advisory Board), Recordati (Writing Committee), and Sparrow Therapeutics (Grant Recipient).
Juan Carl Pallais, MD, MPH Alesta Therapeutics (Consultant), Alexion Pharmaceuticals Inc. (Grant Recipient), Alexion Pharmaceuticals Inc. (Honorarium Recipient), Ensho Health (Advisory Board), Soft Bones (Speakers' Bureau), UpToDate (Author).
Troy H. Puar, MBBS, PhD AstraZeneca (Clinical Trial and Travel Grant).
Richard J. M. Ross, MBBS, MD Neurocrine (Consultant).
Anand Vaidya, MD, MMSc AstraZeneca (Consultant), Corcept (Consultant), Doris Duke Charitable Foundation (Grant Recipient), Mineralys (Advisory Board), and NIH (Grant Recipient).
Benjamin Wilson, BA Neurocrine Biosciences (Consultant).
Lori J. Wirth, MD AbbVie Inc (Advisory Board), Bicara (Advisory Board), Coherus (Advisory Board), EISAI (Consultant), Fore Biopharma (Advisory Board), Leo Pharma (Advisory Board), Novartis (Consultant), Pyxis (Advisory Board), and Tubulis (Advisory Board).
Kevin C. J. Yuen, MD Ascendis Pharma (Advisory Board and Contracted Research), Camurus (Advisory Board), Chiesi (Advisory Board), Crinetics (Advisory Board), Neurocrine (Advisory Board and Speakers' Bureau), Novo Nordisk (Advisory Board, Contracted Research, and Speakers' Bureau), Recordati (Advisory Board and Speakers' Bureau), and Sparrow Therapeutics (Contracted Research).
The following faculty reported no relevant financial relationships:
José O. Alemán-Diaz, MD, PhD; Dalal S. Ali, MD, MSc; Irina Bancos, MD, MSc; Angela M. Cheung, MD, PhD, CCD; Miguel Debono, MD, PhD; Martin den Heijer, MD, PhD; Guido Di Dalmazi, MD; Sorahia Domenice, MD; Juliana Beaudette Drummond, MD, PhD; Aoife Maria Egan, MB BCh, BAO, PhD; Alexander T. Faje, MD; Erin Finn, MD; Peyman Hadji, MD; Niki Karavitaki, MBChB, MSc, PhD; David Suphadetch Leungsuwan, MBBS, MMed; George Mastorakos, MD, DmedSc, MSc; Michael T. McDermott, MD; Berenice B. Mendonca, MD; Kalpana Muthusamy, MBBS, MD; Anna Nordenström, MD, PhD; Georgia Ntali, MBChB, MSc, PhD; Christina Pamporaki, MD, PhD; Robin Peeters, MD, PhD; Mabel Ryder, MD; Pankaj Shah, MD; Omair A. Shariq, MBBS, PhD; Vinaya Simha, MD; Beatriz Sanatana Soares, MD, PhD; Harilena Tsourouktsoglou, MD; and Georgios Valsamakis, MD, PhD.
The following AMSC peer reviewers reported relevant financial relationships:
Barbara Gisella Carranza Leon, MD Novartis, IONIS Pharmaceutical Inc, NIH, FH Foundation, Regenxbio, Inc (Coinvestigator), Maintenance of Certification Committee: American Board of Obesity Medicine (Member).
Diane Donegan, MB BCh BAO, MRCPI Corcept, Recordati (Investigator); Camarus (Advisory Board).
Christa E. Flueck, MD European Society Paediatric Endocrinology (Advisory Board); Novo Nordisk, Merck, Pfizer, Sandoz, Swiss National Science Foundation, European Society Paediatric Endocrinology (Grant Recipient); Novo Nordisk, Pfizer, EffRx (Consultant); Sandoz (Speaker); Hormone Research Paediatrics (Editor).
Oksana Hamidi, DO Corcept Therapeutics, Crinetics Pharmaceuticals, Neurocrine Biosciences, Recordati Rare Diseases, Camurus (Advisory Board); Xeris Pharma (Speaker).
Edward Chiaming Hsiao, MD, PhD International FOP Association, FD/MAS Alliance, International Clinical Council on FOP (Advisory Board); Endocrine Journal, Journal of Bone and Mineral Research (Editor); Clementia Pharmaceuticals/Ipsen Pharmaceuticals, Ultragenyx (Research Investigator).
Suzanne Jan De Beur, MD American Society of Bone and Mineral Research (Past President); XLH Network, Current Osteoporosis Reports, Ultragenyx, Kyowa Kirin, Ascendis (Advisory Board); Bone Reports (Editorial Board); Mereo, Kyowa Kirin, Calcilytics (Researcher); NIH, FDA (Grant Reviewer); PCORI (Investigator).
Peter Kamenicky, MD, PhD Inserm (Member of Commission Scientifique Spécialisée CSS3); Pfizer (Speaker); Amolyt Pharma (Investigator and Speaker); Ascendis Pharma (Advisory Board); and Calcilytix (Investigator).
Srividya Kidambi, MD TOPS Inc (Medical Editor and Director).
Katja Kiseljak-Vassiliades, DO HRA Pharma (Advisory Board).
Raghavendra Mirmira, PhD, MD Journal of Clinical Endocrinology and Metabolism (Editor); Veralox Therapeutics (Advisory Board); Veralox Therapeutics, HiberCell, Inc (Investigator-Initiated Award).
Connie Baum Newman, MD Food and Drug Association (FDA) for Endocrinologic and Metabolic Diseases (Advisory Committee and Consultant); Federation of Medical Women of Canada (Honorarium).
Theodora Pappa, MD, PhD Endocrine Fellows Foundation (Board of Directors), Frontiers (Editorial Board Member), Clinical Thyroidology (Associate Editor), and Eisai (Consultant).
Elizabeth N. Pearce, MD, MSc Iodine Global Network (Management Council); Journal of Clinical Endocrinology and Metabolism, DynaMed-thyroid (Editor); National Dairy Council, Merck China Symposium (Speaker); American Thyroid Association (Guidelines Task Force); World Health Organization (Advisory Panel).
Luca Persani, MD, PhD Merck, Egetis, Sandoz (Advisory Board); Merck (Speaker); Journal of Clinical Endocrinology and Metabolism, European Thyroid Association, European Thyroid Journal, Pituitary Society, Pituitary (Editor).
Laura Torchen, MD Levo therapeutics, IBSA Pharma (Investigator)
Elena Tsourdi, MD Amgen, Kyowa Kirin, UCB, Alexion, Ascendis (Clinical Studies); Amgen, UCB, Ascendis (Advisory Boards and Lectures); UCB, Takeda, Ascendis (Educational Grants)
Adina Turcu, MD, MS NIH/NIDDK/NHLBI (Grant Recipient), ESAP (Questions Writer), JCEM: Case Reports (Deputy Editor), and AstraZeneca (Advisor).
Corrine Kolka Welt, MD UpToDate.
The following AMSC members reported no relevant financial relationships:
Ana Paula Abreu Metzger, MD, PhD; Olga Astapova, MD, PhD; Laura Boucai, MD; Ana Pinheiro Machado Canton, MD, PhD; Hebatullah M. Ismail, MD; Julie Refardt, MD, PhD; and Jun Yang, MBBS, PhD.